Barclays Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $32
Barclays analyst Peter Lawson maintains $Syndax Pharmaceuticals(SNDX.US)$ with a buy rating, and maintains the target price at $32.According to TipRanks data, the analyst has a success rate of 44.1% a
Express News | JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Maintains $34 Price Target
Express News | Syndax Pharmaceuticals Inc : JP Morgan Adds Stock to Its U.S. Analyst Focus List
Syndax Pharmaceuticals Welcomes New Board Member, Passes Resolutions
Express News | Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.d., Ph.d. to the Board of Directors
Syndax Pharmaceuticals (SNDX) Gets a Buy From Stifel Nicolaus
Express News | Citigroup Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $30
Syndax Pharmaceuticals Is Maintained at Buy by Stifel
Syndax Pharmaceuticals Is Maintained at Buy by Stifel
Express News | Syndax Pharmaceuticals Inc : Stifel Raises Target Price to $40 From $39
Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference
Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Express News | HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $41 Price Target
Syndax Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 83.2% HC Wainwright & Co. → $41 Reiterates Buy → Buy 04/26/2024 83.2% HC Wainwright & Co. → $41
Buy Rating for Syndax Pharmaceuticals Amid Strong Financials and Promising Drug Candidate
Express News | Syndax Pharmaceuticals Inc : Guggenheim Cuts Target Price to $35 From $43
Analysts' Top Healthcare Picks: Elanco Animal Health (ELAN), Syndax Pharmaceuticals (SNDX)
Syndax Pharmaceuticals Q1 Net Loss Widens
Syndax Pharmaceuticals (SNDX) reported a Q1 net loss Wednesday of $0.85 per diluted share, wider than a loss of $0.59 a year earlier. Analysts polled by Capital IQ expected a loss of $0.97. The compan
Express News | Syndax Pharmaceuticals Q1 2024 GAAP EPS $(0.85) Beats $(0.99) Estimate
Syndax Pharmaceuticals | 10-Q: Quarterly report
Express News | Syndax Pharmaceuticals Inc - Has Sufficient Cash Runway to Fund Its Research, Clinical Development and Commercial Operations Through 2026
Express News | Syndax Pharmaceuticals Inc - for Full Year of 2024, Company Continues to Expect Research and Development Expenses to Be $240 to $260 Mln